Comparative Pharmacology
Head-to-head clinical analysis: MYTREX F versus SULFATRIM SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX F versus SULFATRIM SS.
MYTREX F vs SULFATRIM-SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell activity.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal synergy.
Oral methotrexate 7.5-25 mg once weekly; subcutaneous methotrexate 7.5-25 mg once weekly; intravenous methotrexate 50-200 mg/m² every 2-3 weeks for oncology indications.
1 double-strength tablet (160 mg trimethoprim / 800 mg sulfamethoxazole) orally every 12 hours for 10-14 days.
None Documented
None Documented
3.5 hours (terminal); prolonged to 8-12 hours in renal impairment.
SMX: 9-12 hours (increased in renal impairment); TMP: 8-11 hours (increased in renal impairment); both prolonged in elderly.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Renal excretion of unchanged sulfamethoxazole (SMX) approximately 20%, trimethoprim (TMP) approximately 60%; biliary/fecal elimination minor (SMX <5%, TMP <10%).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic